• QIAGEN Finalizes Details for $500 Million Synthetic Share Repurchase
VENLO, the Netherlands – QIAGEN N.V. on December 18 announced the final details for its plan to return approximately $500 million to shareholders through a synthetic share repurchase. The transaction, set for completion in early January 2026, combines a direct capital repayment with a reverse stock split.
What is new?
QIAGEN has detailed its plan to complete a synthetic share repurchase valued at approximately $500 million.
This action follows shareholder approval at the Annual General Meeting in June 2025. The company stated this method returns cash to shareholders more efficiently than a traditional open-market program and enhances earnings per share (EPS) by reducing the number of outstanding shares. With the completion of this repurchase, QIAGEN will have returned over $1 billion to shareholders since the start of 2024, ahead of its goal to return at least $1 billion by the end of 2028.
Transaction Details
The repurchase will be conducted through a reverse stock split where every 20 issued QIAGEN shares will be consolidated into 19 shares. This is expected to reduce the number of issued shares by approximately 10.9 million from the 217.7 million outstanding as of December 18, 2025, representing an approximate 5% reduction. Following the consolidation, shareholders of record will receive a capital repayment of $2.29 per pre-consolidation share. The payment will be made in U.S. dollars, although the par-value of the company’s shares is denominated in euros.
Timeline and Trading
The last day of trading for pre-split shares on the New York Stock Exchange and the Frankfurt Stock Exchange is scheduled for Wednesday, January 7, 2026. Trading of the new, consolidated shares is expected to begin on Thursday, January 8, 2026, under the existing ticker symbols QGEN (NYSE) and QIA (Frankfurt). The consolidated shares will be assigned new security identifiers, including ISIN NL0015002SN0 and CUSIP N72482 156. The capital repayment is planned to be made to shareholder accounts in the days following the consolidation. The company has advised shareholders to consult their bank or broker with questions on the mechanics of the transaction.
About this company
QIAGEN N.V., a Netherlands-based holding company, provides Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples. Its sample technologies isolate and process DNA, RNA, and proteins from materials such as blood and tissue. The company’s assay technologies prepare these biomolecules for analysis, while its bioinformatics software supports data interpretation to provide actionable insights. QIAGEN also offers automation solutions to integrate these steps into streamlined workflows.
—
Related Topics
Qiagen N.V. Offers $500M Convertible Bonds Due 2031, 2.5% Coupon, 44% Premium
Update: Postal Worker Emoji Proposal Rejected By Unicode Consortium
DHL and Hapag-Lloyd Partner to Decarbonize Global Supply Chains